In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its ...

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug ...

Futures are trading higher as we get ready to start the first full week of trading for the third quarter, as traders and ...

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

It could prove to be a case of better later than never for the healthcare giant.

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 billion 2023 acquisition of Seagen failed to improve survival when compared to ...

David Denton’s appointment, effective Aug. 17, comes as the company struggles to execute a turnaround, with sales dropping in ...

The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.